CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Endologix, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Endologix, Inc.
2 Musick
Phone: (949) 598-4741p:949 598-4741 Irvine, CA  92618-1631  United States Fax: (949) 699-9622f:949 699-9622

This company ceased filing statements with the SEC on 10/1/2020.
This company is no longer actively traded on any major stock exchange.

Business Summary
Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company’s products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company’s solution for sealing the aneurysm sac while maintaining blood flow. The Company’s EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company’s EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202012/31/2019YesYesYes-Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Daniel T.Lemaitre 66 2/6/2017 12/11/2009
Chief Executive Officer, Director JohnOnopchenko 61 5/2/2018 10/30/2017
Interim Chief Financial Officer CindyPinto 52 7/1/2020 7/1/2020
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Nellix, Inc. 2 Musick Irvine CA United States
TriVascular Technologies, Inc. 2 Musick Irvine CA United States
TriVascular, Inc. 2 Musick Irvine CA United States
PQ Bypass Inc. 269 North Mathilda Avenue Sunnyvale CA United States

Business Names
Business Name
CVD/RMS Acquisition Corp.
ELGX
ELGX International Holdings GP
20 additional Business Names available in full report.

General Information
Outstanding Shares: 20,657,178 (As of 8/4/2020)
Shareholders: 84
Stock Exchange: OTC
Federal Tax Id: 680328265
Fax Number: (949) 699-9622
Email Address: investorrelations@endologix.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 1, 2024